Boehringer Ingelheim Press Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind ® (idarucizumab) Usage in Clinical Practice
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 14, 2016 Category: Research Source Type: news

First Study Initiated to Evaluate the Effect of Ofev ® Treatment on Biomarkers that may Predict IPF Progression
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 26, 2016 Category: Research Source Type: news

Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials following pre-planned analysis from independent Data Monitoring Committee
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 24, 2016 Category: Research Source Type: news

U.S. FDA expands indication for type 2 diabetes treatment Synjardy ® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 18, 2016 Category: Research Source Type: news

U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 18, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - July 12, 2016 Category: Research Source Type: news

FDA Advisory Committee recommends approval of Jardiance ® (empagliflozin) for cardiovascular indication   in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor   of CV mortality benefit for JARDIANCE for adults with type 2 diabetes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 27, 2016 Category: Research Source Type: news

FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 27, 2016 Category: Research Source Type: news

New analysis of INPULSIS ™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 26, 2016 Category: Research Source Type: news

New analysis of INPULSIS™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 26, 2016 Category: Research Source Type: news

Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 13, 2016 Category: Research Source Type: news

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 13, 2016 Category: Research Source Type: news

New Jardiance ® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 11, 2016 Category: Research Source Type: news

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 11, 2016 Category: Research Source Type: news

New study results show Tradjenta ® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 10, 2016 Category: Research Source Type: news